�Destiny Pharma plc
�
("Destiny Pharma" or "the Company")
�
Director/PDMR Shareholding
�
Brighton, United Kingdom - 5 June 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that Sir Nigel Rudd, Non-Executive Chairman of the Company, has today notified the Company that, on 4 June 2018, he and his wife have purchased a total of 74,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 110.04 pence per share.
�
Following this notification, Sir Nigel Rudd, together with connected parties, has a beneficial holding of 1,229,900 Ordinary Shares (which represents 2.82 per cent. of the issued share capital of the Company).
�
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
�
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) � |
Name � |
Sir Nigel Rudd |
||||
|
2 |
Reason for the notification |
|||||
|
a) � |
Position/status |
Non-Executive Chairman |
||||
|
b) |
Initial notification �/ Amendment |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) � |
Name � |
Destiny Pharma plc |
||||
|
b)
|
LEI
|
213800O9WH9Z38EHAC95 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code: |
Ordinary shares of 1 pence each ISIN: GB00BDHSP575 |
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares into ISA |
||||
|
c)
|
Price(s) and volume(s) |
|
||||
|
d)
|
Aggregated information
|
N/A |
||||
|
e)
|
Date of the transaction |
4 June 2018 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name
|
Lady Lesley Rudd |
||||
|
2 |
Reason for the notification |
|||||
|
a)
|
Position/status |
Person closely associated to Sir Nigel Rudd, Non-Executive Chairman |
||||
|
b) |
Initial notification / Amendment |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Destiny Pharma plc |
||||
|
b)
|
LEI
|
213800O9WH9Z38EHAC95 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code: |
Ordinary shares of 1 pence each ISIN: GB00BDHSP575 |
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares into ISA |
||||
|
c)
|
Price(s) and volume(s) |
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e)
|
Date of the transaction |
4 June 2018 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
||||
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com